menu
    • menu
    [{"orgOrder":0,"company":"Innovative Molecules","sponsor":"Life Sciences Partners","pharmaFlowCategory":"D","amount":"$23.7 million","upfrontCash":"Undisclosed","newsHeadline":"Innovative Molecules Raises \u20ac20 Million Series A Equity Financing Round","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Series A Financing","leadProduct":"IM-250","moa":"Helicase-primase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Innovative Molecules","amount2":0.02,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Innovative Molecules \/ Life Sciences Partners","highestDevelopmentStatusID":"4","companyTruncated":"Innovative.."}]

    Find Clinical Drug Pipeline Developments & Deals by Innovative Molecules

    Menu

    Innovative Molecules

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Innovative Molecules

                            Germany arrow
                            Formnext Forum
                            Not Confirmed

                            Innovative Molecules

                            Germany arrow
                            Formnext Forum
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IM-250

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Life Sciences Partners

                            Deal Size : $23.7 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Innovative Molecules Raises €20 Million Series A Equity Financing Round

                            Details : The company will use the funds to advance its preclinical product candidate, IM-250, from the current late preclinical stage to a Phase 2 proof-of-concept study. IM-250 is a potent inhibitor of Herpes Simplex Virus type 1 (HSV-1) and type 2 (HSV-2) repli...

                            Brand Name : IM-250

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            June 07, 2021

                            Lead Product(s) : IM-250

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Life Sciences Partners

                            Deal Size : $23.7 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth